Early market access of cancer drugs in the EU.

Early market access of cancer drugs in the EU.

Item
http://www.wikidata.org/entity/Q38612833
"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Evaluating beneficial drug effects in a non-interventional setting: a review of effectiveness studies based on Swedish Prescribed Drug Register data.Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.Economics of ramucirumab for metastatic colorectal cancer.European Medicines Agency Perspective on Oncology Study Design for Marketing Authorization and Beyond.Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study.Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer.
P2860

Early market access of cancer drugs in the EU.

Item
http://www.wikidata.org/entity/Q38612833
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Early market access of cancer drugs in the EU.
@en
type
label
Early market access of cancer drugs in the EU.
@en
prefLabel
Early market access of cancer drugs in the EU.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Early market access of cancer drugs in the EU.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698